Welcome to the real world Matthew Gordon examines the differences between observational studies and phase III clinical trials(more)
Drug regulation: still room for improvement The Medicines Act is 40 years old this year, but regulations and regulators have to change to keep up with rapid changes in medicines and society, says Les Rose.(more)
Kicking the habit on prescription Tuesday , December 31, 2002
Once blacklisted, NRT prescriptions almost tripled in 2002 and are now central to the Government's war on smoking. Pharmafocus investigates this uniquely dynamic market....(more)
The European private pharma sector Monday , December 30, 2002
How do private pharmaceutical companies in Europe compare with their public counterparts and how might they compete in fut...(more)
E-learning: a bitter pill or miracle cure? Monday , December 30, 2002
Pharma is often seen as an ideal industry to benefit from e-learning but how should it be implemented and what do the companies themselves think? ...(more)
Usability: mumbo jumbo or magic bullet? Tuesday , December 10, 2002
Usability, usability, usability. It's a new mantra you will be hearing more of in the coming months. But is it just another piece of jargon you can safely ignore - or is it the key to the success of your on-line communications? ...(more)
Concept testing: the collision of two worlds Tuesday , December 10, 2002
Testing pharmaceutical adverts in front of doctors is a well-worn practice, but perhaps one that could do with updating as both the NHS and pharma keep changing. ...(more)
The pharmaceutical doll's house Tuesday , December 10, 2002
How can biotech companies avoid the organisational straitjacket restricting pharma?...(more)
